Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Now trading at $24. I suppose your opinion was incorrect “Vin”

Not sure what opinion you think of mine was incorrect. I will buy more at this discounted price.

EDP-235 met the primary endpoint of the trial and was generally safe and well-tolerated. A dose-dependent improvement in symptoms was observed with EDP-235 treatment compared to placebo, which achieved statistical significance (p<0.05) in the 400mg treatment group at multiple time points, starting as early as one day after the first dose. In a prespecified population consisting of patients enrolled within 3 days of symptom onset, a statistically significant improvement was observed with EDP-235 at 400mg at all time points.

That is something Paxlovid failed to do.